In 2019, sales of Demei Medical are expected to reach tens of millions of RMB.
It is reported that the domestic sports and rehabilitation medicine brand “Demei Medical” recently announced the completion of tens of millions of RMB C round of financing. This round of financing is led by Qiming Venture Capital, which will be used for the company’s next core product research and development, marketing and improvement of the business environment.
Before, Demei Medical was also awarded the RM10 million B round of financing by Yuansheng Venture Capital and Botong Capital in April 2018.
Beijing Deyi Damei Medical Technology Co., Ltd. (hereinafter referred to as: Demei Medical) was founded in 2015, is a company dedicated to providing a comprehensive range of sports medicine treatment integration solutions. Its products include traumatic titanium alloy cables, orthopedic external fixators and other trauma series; sports medicine sutures, cruciate ligament reconstruction surgical instruments and other medical series; knee joints, ankle brace and other brace series.
In addition, Demei Medical also provides services such as disease science, disease consultation, symptomatic recommendation for rehabilitation products, rehabilitation program enquiries, and physical therapy appointments on the WeChat public account. Under the line, a sports rehabilitation brand named “Riteng Rehabilitation” was created. The client provides exercise rehabilitation guidance and treatment.
In terms of core technology, Demei Medical currently has a number of international patents, more than a dozen Chinese invention patents, and dozens of utility model patents. And set up a factory in Liandong U Valley Technology Industrial Park, Tongzhou District, Beijing. The factory has a complete set of machining and surface treatment production lines.
And testing equipment, as well as in line with orthopedic class III implant production
The required 10,000-grade purification packaging workshop.
At present, more than 500 domestic and foreign customers and institutions have reached a cooperative relationship with Demei Medical. The products cover the whole country and are also tested in overseas regions such as Korea, Japan, Singapore, Southeast Asia and Europe. Li Jianbo, Li Jianbo, co-founder and general manager of Dermei Medical, said: “In 2019, the sales of Demei Medical is expected to reach tens of millions of yuan.”
In terms of investment logic, Zhang Qi, an executive director of Qiming Venture Capital, and Li Zhenming, a capital partner of Bohang, came to the following two points: one is optimistic about the development of sports medicine in China, and the other is optimistic about the founding team. Execution and leadership.
If you look at the global sports medicine market, Stratisics Market Research Consulting forecast,Global Sports Medicine Market, valued at $5.1 billion in 2017, is expected from 2017 By 2026, it will grow at a compound annual growth rate of 9.8% and grow to a market of US$11.9 billion in 2026.
The report of the arterial network shows that the Chinese people generally lack clear understanding of sports rehabilitation, the body After the function, the situation tends to “I want to cure the disease” rather than “how to restore the body function”, so the per capita consumption of sports rehabilitation in the United States is more than 6 times higher than that of China. Players currently participating in this market in China also have excellent clinics, Technology, Additional Health, < a href="https://36kr.com/p/5056980.html">Rehabilitation Masters and so on.